tucatinib


( Last Updated : October 19, 2021)
Generic Name:
tucatinib
Project Status:
Active
Therapeutic Area:
Advanced or Metastatic Breast Cancer
Manufacturer:
Seagen Canada Inc.
Call for patient/clinician input open:
Brand Name:
Tukysa
Project Line:
Reimbursement Review
Project Number:
PC0243-000
Call for patient/clinician input closed:
Tumour Type:
Breast
NOC Status at Filing:
Post NOC

Details


Manufacturer Requested Reimbursement Criteria1:
In combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
‚ÄčTucatinib is indicated in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination.
Date NOC Issued:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

 

Key Milestones2

Call for patient/clinician input open February 26, 2021
Clarification:

- Patient input submission received from Canadian Breast Cancer Network and Rethink Breast Cancer

Call for patient/clinician input closed April 23, 2021
Submission received March 26, 2021
Submission accepted April 12, 2021
Review initiated April 13, 2021
Draft CADTH review report(s) provided to sponsor for comment June 25, 2021
Deadline for sponsors comments July 07, 2021
CADTH responses on draft review report(s) provided to sponsor August 26, 2021
Expert committee meeting (initial) September 08, 2021
Draft recommendation posted for stakeholder feedback October 1, 2021
End of feedback period October 18, 2021